Prohost Letters
Premium
Prohost Letter #393
Prohost Letter #393 IMMUNOTHERAPY - PROHOST PORTFOLIO - NEW PICKS? - A Brief Reminder of the CAR T –TCR Immunotherapy Approaches In this issue we continue our journey inside the territory of cancer...
P
Prohost Biotech
1 min read
11
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Tags
AdaptImmune Therapeutics (ADAP)
Advaxis (ADXS)
Agenus (AGEN)
Amgen (AMGN)
Ariad Pharmaceuticals (ARIA)
Array BioPharma (ARRY)
AstraZeneca Plc (AZN)
Bellicum Pharmaceuticals Inc (BLCM)
Bristol-Myers Squibb (BMY)
CAR-T
Celldex Therapeutics (CLDX)
Cellectis (CLLS)
Compugen (CGEN)
Exelixis (EXEL)
Five Prime Therapeutics (FPRX)
Incyte (INCY)
Jounce Therapeutics (JNCE)
Juno Therapeutics (JUNO)
Kite Pharma - A Gilead Company
Medivation (MDVN)
Merck (MRK)
Pfizer (PFE)
Prohost Portfolio
Roche (RHHBY)
Seagen Inc (SGEN)
Ziopharm Oncology (ZIOP)
Comments (0)
Please sign in to join the discussion